44 results about "Retina Neovascularization" patented technology

The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle. The therapeutic agents may be selected from the group consisting of angiogenesis inhibitors and complement inhibitors.

The present invention provides compositions and methods of treating neovascular diseases, such as a retinal neovascular diseases and tumors, by administering to a patient suffering from a neovascular disease or tumor a vascular development inhibiting amount of a combination of the angiogenesis suppressing drugs comprising an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one compound selected from the group consisting of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor. Compositions for use in the methods include an admixture of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor, together with a pharmaceutically acceptable excipient.

The present invention discloses an integrin blocking agent polypeptide and applications of the same in preparation of drugs for treatment of neovascular eye diseases, and belongs to the field of medicine. The integrin blocking agent polypeptide comprises a polypeptide I Arg-Gly-Asp-Gly-Gly-Gly-Gly-Phe- Gln-Pro-Val-Leu-His-Leu-Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Ala-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala and a polypeptide II Phe-Gln-Pro-Val-Leu-His-Leu-Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Al a-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala-Gly-Gly-Gly-Gly-Arg-Gly-Asp, wherein the polypeptide I is modified with the integrin ligand sequence (Arg-Gly-Asp-Gly-Gly-Gly-Gly). The integrin blocking agent polypeptide can be used for treatments of iridal neovascular eye diseases, choroidal neovascular eye diseases, retinal neovascular eye diseases or corneal neovascular eye diseases and other neovascular eye diseases.

The invention provides application of transthyretin in the aspect of serving as a carrier for a protein and / or polypeptide drug to enter an eye through an eye barrier. The transthyretin is a protein consisting of amino acid as shown in SEQ ID NO:1 or a mutation thereof or a modification thereof. The invention further provides application of the transthyretin and / or a fusion protein of the transthyretin and a drug to preparation of a drop and a drop. The drug is the protein and / or polypeptide drug. The transthyretin has good biocompatibility and safety in human bodies, can effectively convey aforeign protein and / or polypeptide into the eye and achieves an effect of treating eye diseases. In an eye dropping manner, when the eye diseases such as DR (Diabetic Retinopathy), AMD (Age-related macular degeneration), ROP (Retinopathy of Prematurity) and the like are treated, the transthyretin can enter a vitreous body and eye ground across a cornea barrier so as to obviously inhibit eyeball retina leakage, obviously reduce the number of retinal new blood vessels and effectively relieve the pathological phenomena of the eye diseases.

The invention discloses a retinal neovascularization detection method for a color fundus image. The method comprises the steps of obtaining color fundus image data and performing preprocessing to obtain training data; constructing a deep learning network model for retinal neovascularization detection; training the deep learning network model by adopting the training data to obtain a retinal neovascularization detector; preprocessing the color fundus image data to be detected; adopting a retinal neovascularization detector to detect the preprocessed to-be-detected color eye fundus image data toobtain a prediction probability graph of pixels judged as retinal neovascularization in the to-be-detected color eye fundus image; and carrying out thresholding processing to obtain a final detectionresult of the retinal neovascularization in the to-be-detected color fundus image. The invention further discloses an imaging method comprising the retinal neovascularization detection method for thecolor fundus picture. The device is high in reliability, good in practicability and good in detection effect.

The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and / or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy.

The invention discloses a construction method and application of a retinal neovascularization disease model, and relates to the field of biotechnology. The construction method knocks out the Tmem30a gene sequence in the genome of the target animal vascular endothelial cells, so that the target animal exhibits the typical retinal neovascularization disease characteristics. The target animal can beused as a model of retinal neovascularization disease, which can help to clarify the pathogenesis and mechanism of retinal neovascularization disease, and provide a new target for the treatment or prevention of retinal neovascularization disease.

The invention provides an ophthalmic preparation as well as a preparation method and application thereof. The invention discloses an ophthalmic preparation for inhibiting ocular retinal leakage and / or reducing the number of retinal neovascularization. The ophthalmic preparation comprises vitamin A or pharmaceutically acceptable salt thereof and transthyretin, the transthyretin is a protein composed of amino acids as shown in SEQ ID NO: 1. The content of the transthyretin is 5 to 30 [mu] mol / L; the content of the vitamin A or the pharmaceutically acceptable salt thereof is 2-10 [mu] mol / L. The invention also provides a preparation method and application of the ophthalmic preparation. The transthyretin and the compound in the ophthalmic preparation can cooperate with each other, so that the treatment effect on eye diseases related to eye angiogenesis and / or eye retina leakage can be remarkably improved when the ophthalmic preparation is used for treating the eye diseases.

The present invention relates to the use of a VEGF antagonist in the treatment of retinal neovascular disorders in infants. In particular, the invention provides a method for treating an infant having retinopathy of prematurity (ROP), wherein said method comprises administering to the eye of an infant a VEG F antagonist that either does not enter or is rapidly cleared from the systemic circulation. The term infant is typically used to refer to young children from birth up to the age of 12 months. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops.

The invention discloses a method and application for constructing a retinal neovascularization disease model, and relates to the field of biotechnology. Specifically, this method knocks out the Ctnna1 gene in the vascular endothelial cells of the target animal through gene editing technology, or silences the expression of the Ctnna1 gene in the vascular endothelial cells of the target animal through RNAi technology, so that the target animal shows typical retinal neogenesis The characteristics of vascular diseases, the disease model can be used as a disease model of new retinal blood vessels, and it provides convenience for the study of the pathogenesis and mechanism of retinal neovascular diseases, and also provides a new target for the treatment or prevention of the disease .